Frenelle is developing FRN01, a once-monthly subcutaneous buprenorphine injection for Opioid Use Disorder (OUD), and is backed by Mayo Clinic Ventures.
Jeff Missling, CEO
jmissling@frenellepharma.com
https://www.frenellepharma.com/